Last reviewed · How we verify

NCT06768736

Early Warning System for Allergic Rhinitis in the MASK-air® App

Not yet recruiting NA Last updated 6 February 2025
What this trial tests

NA trial testing Personalised early warning system in Allergic Rhinitis in 210 participants. Not yet recruiting.

Timeline
30 January 2025
Primary endpoint
15 January 2026
15 May 2026

Quick facts

Lead sponsorUniversidade do Porto
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposehealth services research
Enrollment210
Start date30 January 2025
Primary completion15 January 2026
Estimated completion15 May 2026
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Universidade do Porto — full company profile →

Who can join

18 and older, any sex, with Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective consists in the comparison of the combined symptom medication score values between (i) patients randomised to the early warning system personalised forecasting messages, and (ii) patients randomised to generic messages already delivered by MASK-air®. The combined symptom medication score has recently been developed in a data-driven way and validated (https://eaaci.org/images/CSMS.pdf); it assesses allergic rhinitis control taking into account both reported symptoms and medication use. As secondary objectives, visual analogue scales on allergic rhinitis symptoms (VAS global, nasal, eye, asthma), and medication use will also be separately compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Allergic Rhinitis

Currently open trials in the same condition.

Other Universidade do Porto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06768736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing